Finally, combining Leone’s report (19) and our results, we think that it is necessary to investigate the clinical value of a combined SLC1A5 inhibitor (or glutamine inhibitor, alternatively) and an immune-checkpoint inhibitor for treating LGG or HCC patients. The gene discussed is SLC1A5; the disease is hepatocellular carcinoma.